Results that matter: Structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 97, Issue 1, 2012, Pages 6-15

  Parkin, Christopher G ^a   Buskirk, Ann ^b   Hinnen, Deborah A ^c   Axel Schweitzer, Matthias ^d  

^a CGParkin Communications Inc   (United States)

^b ALBuskirk   (United States)

^c Mid America Diabetes Associates PA   (United States)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Clinical trials; Glucose monitoring; Structured SMBG; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; BODY MASS; CARDIOVASCULAR RISK; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT EDUCATION; POSTMARKETING SURVEILLANCE; POSTPRANDIAL STATE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STRUCTURED BLOOD GLUCOSE MONITORING; UNSTRUCTURED BLOOD GLUCOSE MONITORING; WEIGHT REDUCTION;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864090935     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.03.002     Document Type: Review

References (47)

1. International Diabetes Federation Clinical Guidelines Taskforce and International SMBG Working Group. Global guideline on self-monitoring of blood glucose in non-insulin treated type 2 diabetes; 2009. Accessed March 1, 2011 from http://www.idf.org/.
2. Austin M.M., Haas L., Johnson T., Parkin C.G., Parkin C.L., Spollett G., et al. Self-monitoring of blood glucose: benefits and utilization. Diabetes Educ 2006, 32(6):835-837.
3. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
4. Karter A.J., Ackerson L.M., Darbinian J.A., D'Agostino R.B., Ferrara A., Liu J., et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser permanente diabetes registry. Am J Med 2001, 111(1):1-9.
5. Nathan D.M., McKitrick C., Larkin M., Schaffran R., Singer D.E. Glycemic control in diabetes mellitus: have changes in therapy made a difference?. Am J Med 1996, 100(2):157-163.
6. Goldstein D.E., Little R.R., Lorenz R.A., Malone J.I., Nathan D.M., Peterson C.M. Tests of glycemia in diabetes. Diabetes Care 2004, 27(Suppl. 1):S91-S93.
7. Farmer A., Wade A., Goyder E., Yudkin P., French D., Craven A., et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007, 335(7611):132.
8. Barnett A.H., Krentz A.J., Strojek K., Sieradzki J., Azizi F., Embong M., et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008, 10(12):1239-1247.
9. Davidson M.B., Castellanos M., Kain D., Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005, 118(4):422-425.
10. Guerci B., Drouin P., Grange V., Bougneres P., Fontaine P., Kerlan V., et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003, 29(6):587-594.
11. Schwedes U., Siebolds M., Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002, 25(11):1928-1932.
12. Glasgow R.E. What types of evidence are most needed to advance behavioral medicine?. Ann Behav Med 2008, 35(1):19-25.
13. Parkin C.G., Hinnen D., Campbell R.K., Geil P., Tetrick D.L., Polonsky W.H. Effective use of paired testing in type 2 diabetes: practical applications in clinical practice. Diabetes Educ 2009, 35(6):915-927.
14. Muchmore D.B., Springer J., Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994, 31(4):215-219.
15. Estey A.L., Tan M.H., Mann K. Follow-up intervention: its effect on compliance behavior to a diabetes regimen. Diabetes Educ 1990, 16(4):291-295.
16. Wing R., Epstein L., Nowalk M., Scott N. Self-regulation in the treatment of type II diabetes. Behav Ther 1988, 19:11-23.
17. Newman W.P., Laqua D., Engelbrecht D. Impact of glucose self-monitoring on glycohemoglobin values in a veteran population. Arch Intern Med 1990, 150(1):107-110.
18. Allen B.T., DeLong E.R., Feussner J.R. Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Randomized controlled trial comparing blood and urine testing. Diabetes Care 1990, 13(10):1044-1050.
19. O'Kane M.J., Bunting B., Copeland M., Coates V.E. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008, 336(7654):1174-1177.
20. Duran A., Martin P., Runkle I., Perez N., Abad R., Fernandez M., et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St. Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. J Diabetes 2010, 2(3):203-211.
21. Polonsky W.H., Fisher L., Schikman C.H., Hinnen D.A., Parkin C.G., Jelsovsky Z., et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011, 34(2):262-267.
22. Franciosi M., Lucisano G., Pellegrini F., Cantarello A., Consoli A., Cucco L., et al. ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomized clinical trial. Diabet Med 2011.
23. Bonomo K., De Salve A., Fiora E., Mularoni E., Massucco P., Poy P., et al. Evaluation of a simple policy for pre- and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin. Diabetes Res Clin Pract 2010, 87(2):246-251.
24. Kempf K., Kruse J., Martin S. ROSSO-in-praxi: a self-monitoring of blood glucose-structured 12-week lifestyle intervention significantly improves glucometabolic control of patients with type 2 diabetes mellitus. Diabetes Technol Ther 2010, 12(7):547-553.
25. Mohan V., Ravikumar R., Poongothai S., Amutha A., Sowmya S., Karkhuzali K., et al. A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in type 2 diabetic subjects. J Diabetes Sci Technol 2010, 4(4):942-948.
26. Kato N.K., Kato M. Use of structured SMBG helps reduce A1C levels in insulin-treated diabetic patients. Diabetes 2011, 60(Suppl. 1):A235-A352.
27. Shiraiwa T., Takahara M., Kaneto H., Miyatsuka T., Yamamoto K., Yoshiuchi K., et al. Efficacy of occasional self-monitoring of postprandial blood glucose levels in type 2 diabetic patients without insulin therapy. Diabetes Res Clin Pract 2010, 90(3):e91-e92.
28. Kleefstra N., Hortensius J., Logtenberg S.J., Slingerland R.J., Groenier K.H., Houweling S.T., et al. Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). Neth J Med 2010, 68(1):311-316.
29. Chidum E., Agbai D., Fidelis O., Teppany S., Martina R., Rian E., et al. Self-monitoring of blood glucose improved glycaemic control and 10-year coronary heart disease risk profile of type 2 diabetic patients. Chin Med J (Engl) 2011, 124(2):166-171.
30. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371(9626):1753-1760.
31. Chen H.S., Wu T.E., Jap T.S., Hsiao L.C., Lee S.H., Lin H.D. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31(10):1927-1932.
32. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
33. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591.
34. Peel E., Douglas M., Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients' perspectives. BMJ 2007, 335(7618):493.
35. Lalic N.T.T., Mourredine M., Parkin C.G., Schweppe U., Aman-Zalan I. Value and utility of structured self-monitoring of blood glucose (SMBG) in real world clinical practice: findings from a multinational observational study. Diabetes Technol Ther 2012, 14(4). 10.1089/dia.2011.0186.
36. Shiraiwa T., Kaneto H., Miyatsuka T., Kato K., Yamamoto K., Kawashima A., et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 2005, 336(1):339-345.
37. Sorkin J.D., Muller D.C., Fleg J.L., Andres R. The relation of fasting and 2h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005, 28(11):2626-2632.
38. Group D.S. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161(3):397-405.
39. Levitan E.B., Song Y., Ford E.S., Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004, 164(19):2147-2155.
40. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39(12):1577-1583.
41. International Diabetes Federation. Guideline Development Committee: Guideline for management of postmeal glucose. International Diabetes Federation; 2011. Available from: http://www.idf.org/guidelines/postmeal-glucose.
42. Hanefeld M., Cagatay M., Petrowitsch T., Neuser D., Petzinna D., Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25(1):10-16.
43. Esposito K., Giugliano D., Nappo F., Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004, 110(2):214-219.
44. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010, 33(2):442-449.
45. Burke G.L., Evans G.W., Riley W.A., Sharrett A.R., Howard G., Barnes R.W., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995, 26(3):386-391.
46. Pi-Sunyer X., Blackburn G., Brancati F.L., Bray G.A., Bright R., Clark J.M., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30(6):1374-1383.
47. Herrnan W.H., Brandle M., Zhang P., Williamson D.F., Matulik M.J., Ratner R.E., et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003, 26(1):36-47.